Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Repatha (evolocumab by Quarter
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M) ($M)
Amgen Repatha (evolocumab: $510M in Q2 2026, up 41.3% from a year earlier.
Latest, Q2 2026
510
Period ended Jun 30, 2026
Change on a year earlier
+41.3%
361 in Q2 2025
History
32 quarters
Since Q3 2018
Sources
27
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Amgen Repatha (evolocumab ($M), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-repatha-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.